Literature DB >> 7526714

Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms.

L P McQuillan1, G K Leung, P A Marsden, S K Kostyk, S Kourembanas.   

Abstract

Normal blood vessel tone is maintained by a balance of vasoconstrictors and vasodilators produced by endothelial cells in the vasculature. Nitric oxide (NO) is a potent vasodilator that causes vascular smooth muscle cell relaxation by elevating intracellular guanosine 3',5'-cyclic monophosphate (cGMP) levels. The physiological mechanisms regulating NO production in the vasculature are not completely understood. We report here that production of this vasodilator by vascular endothelial cells can be significantly suppressed by hypoxia. Exposing human endothelial cells to low PO2 results in 40-60% reduction in the steady-state mRNA levels of endothelial constitutive NO synthase (eNOS), the major enzyme responsible for NO production in these cells. The lower levels of eNOS mRNA result from decreased transcription of the gene as well as reduced message stability. In endothelial-smooth muscle cell co-culture experiments, hypoxic endothelial cells stimulated significantly less cGMP production by smooth muscle cells than the corresponding normoxic controls. This inhibitory effect of hypoxia on NOS production by endothelial cells occurs after 24 h of hypoxia and persists for at least 48 h. These new findings suggest that hypoxia might cause changes in blood vessel tone through compound mechanisms: by increasing the production of endothelium-derived vasoconstrictors and, as shown here, by suppressing the production of vasodilators like NO.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526714     DOI: 10.1152/ajpheart.1994.267.5.H1921

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  79 in total

1.  Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy.

Authors:  R Schulz; D Schmidt; A Blum; X Lopes-Ribeiro; C Lücke; K Mayer; H Olschewski; W Seeger; F Grimminger
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

2.  The role of 3'-untranslated region (3'-UTR) mediated mRNA stability in cardiovascular pathophysiology.

Authors:  C M Misquitta; V R Iyer; E S Werstiuk; A K Grover
Journal:  Mol Cell Biochem       Date:  2001-08       Impact factor: 3.396

Review 3.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

Review 4.  Nitric oxide (NO) and obstructive sleep apnea (OSA).

Authors:  James S J Haight; Per Gisle Djupesland
Journal:  Sleep Breath       Date:  2003-06       Impact factor: 2.816

5.  Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  David A Zisman; David J Ross; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Arun S Karlamangla
Journal:  Respir Med       Date:  2007-07-02       Impact factor: 3.415

6.  Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammation in human pulmonary arterial tissue.

Authors:  R Ziesche; V Petkov; J Williams; S M Zakeri; W Mosgöller; M Knöfler; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

7.  Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea.

Authors:  Sanja Jelic; Margherita Padeletti; Steven M Kawut; Christopher Higgins; Stephen M Canfield; Duygu Onat; Paolo C Colombo; Robert C Basner; Phillip Factor; Thierry H LeJemtel
Journal:  Circulation       Date:  2008-04-14       Impact factor: 29.690

8.  Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP.

Authors:  T Morita; M A Perrella; M E Lee; S Kourembanas
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

10.  Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress.

Authors:  Bo Shen; Lee Chao; Julie Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.